Do GLP-1 Drugs Like Ozempic and Wegovy Cause Hair Loss in Men? What the New Genetic Study Shows

A landmark September 2026 study from NYU Langone Health established, for the first time, a direct genetic link between GLP-1 receptor agonist drugs — including Ozempic, Wegovy, and Zepbound — and a 7% increased risk of male-pattern hair loss in men who are already genetically predisposed to androgenetic alopecia. Published September 3 in the Journal of Investigative Dermatology, the findings shift the conversation on GLP-1-related hair loss beyond the commonly cited explanation of rapid weight loss, pointing instead to a shared biological mechanism rooted in the GLP1R gene itself.

The study uses a two-sample Mendelian randomization design — a method that treats genetic variants as proxies for an exposure (here, GLP-1 receptor activity) to infer causal relationships without running a randomized controlled trial. This allowed researchers to isolate the effect of GLP-1 receptor signaling from confounding lifestyle and metabolic factors.

Before diving into the science, here is a side-by-side look at the key studies now linking GLP-1 drugs to hair loss:

Study	Published	Design	Population	Key Finding
NYU Langone / Journal of Investigative Dermatology	Sept. 3, 2026	Mendelian randomization (genetic)	Up to 205,327 men (eQTLGen + CTG databases)	7% added hair loss risk in genetically susceptible men; link persists after controlling for hypertension, insulin resistance, testosterone
University of Pennsylvania / BMJ	July 2026	Observational cohort	~50,000 adults with type 2 diabetes on GLP-1s vs. SGLT-2 or DPP-4 inhibitors	GLP-1 users had 37% higher alopecia risk vs. SGLT-2 users; 68% higher vs. DPP-4 users; primarily non-scarring alopecia
FDA Adverse Event Reporting System (ongoing)	Ongoing	Pharmacovigilance	US GLP-1 users	Regulators evaluating hair loss as a safety signal for semaglutide and tirzepatide
UK MHRA Reports (2025–2026)	2026	Spontaneous reporting	UK GLP-1 users	399 tirzepatide hair loss reports in 2026 YTD; 541 in 2025; 148 semaglutide reports in 2026; 164 in 2025

The convergence of genetic, observational, and pharmacovigilance data across multiple countries makes this one of the more solid emerging safety signals in the GLP-1 drug class.

What exactly did the NYU Langone genetic study find?

The NYU Langone study is the first peer-reviewed research to use genetic methodology to establish a causal link between GLP-1 receptor activity and androgenetic alopecia in men. Led by senior investigator Lynn Petukhova, PhD, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine, the team focused on the GLP1R gene — the gene that governs how many GLP-1 receptor proteins the body produces.

The logic is straightforward: GLP-1 receptor agonist drugs work by binding to GLP-1 receptors and amplifying their activity. Men who naturally carry genetic variants that produce more GLP-1 receptor proteins are, in effect, experiencing a biological analog of what these drugs do pharmacologically. By comparing the genetic profiles of men with high GLP1R activity against those of men with androgenetic alopecia, the researchers could test whether the two overlap more than chance would predict.

They did. Genetic variants associated with naturally higher levels of GLP-1 receptor proteins were significantly more common in men with androgenetic alopecia, yielding that 7% added risk figure.

The team ran three separate sensitivity analyses to rule out alternative explanations:

Hypertension — High blood pressure is a known hair loss risk factor because it can reduce blood flow to the scalp. After adjusting for hypertension, the 7% risk remained unchanged.
Insulin resistance — A cause of type 2 diabetes and a potential confound given that many GLP-1 users have metabolic disease. Adjusting for insulin resistance did not alter the result.
Testosterone levels — Androgens are central to androgenetic alopecia. Accounting for testosterone variation still left the 7% risk intact.

"Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically," said Dr. Petukhova.

The databases used were substantial: the eQTLGen database (31,684 mostly White men and women) and the Complex Traits Genetics group database (205,327 mostly White men). The racial homogeneity of these databases is a genuine limitation — the researchers acknowledge that findings may not generalize equally across all ethnic groups, and future studies with more diverse populations are needed.

How does this differ from the "it's just the weight loss" explanation?

For years, clinicians and drug manufacturers have attributed GLP-1-related hair shedding primarily to telogen effluvium — a well-documented phenomenon where rapid weight loss or caloric restriction pushes hair follicles prematurely into the resting (telogen) phase of the growth cycle. Under this explanation, hair loss is a downstream consequence of losing weight quickly, not a direct effect of the drug itself.

That explanation is not wrong, but the NYU Langone study suggests it is incomplete. The Mendelian randomization design specifically isolates genetic GLP-1 receptor activity from the metabolic effects of weight loss. Because the genetic variants used as proxies predate any drug exposure, the analysis is not confounded by how much weight someone lost or how fast.

The July 2026 BMJ study from the University of Pennsylvania reinforces this complexity. That observational study of roughly 50,000 adults found GLP-1 users had a 37% higher risk of alopecia compared to SGLT-2 inhibitor users and a 68% higher risk compared to DPP-4 inhibitor users — both diabetes drugs that do not cause the same degree of weight loss. If weight loss alone were the culprit, the gap between GLP-1s and these comparators would be smaller.

The BMJ team noted that while reduced caloric intake and micronutrient deficiencies (iron, zinc, biotin) likely play a role, "metabolic, hormonal, and immunological effects attributed to GLP-1 receptor agonists may influence hair follicle growth and cycling" through separate pathways. GLP-1 receptor agonists have been associated with changes in thyroid function, and delayed gastric emptying may alter the absorption of oral medications including thyroid hormone and sex hormone therapies — both of which can affect hair growth through endocrine mechanisms.

Weight loss is a real contributor to hair shedding on GLP-1 drugs, but the genetic study provides evidence that the drug's direct action on GLP-1 receptors may also matter independently.

Who is most at risk — and what does "7% added risk" actually mean in practice?

The 7% figure deserves some unpacking, because it is an added relative risk layered on top of an already substantial baseline.

Androgenetic alopecia is estimated to affect approximately half of White American males over age 50. An additional 7% risk on top of that baseline is meaningful, particularly for men who are already noticing thinning or who have a strong family history of male-pattern baldness.

The risk profile breaks down roughly as follows:

A man with no genetic predisposition to androgenetic alopecia does not appear to carry the same elevated risk from GLP-1 use, based on the current evidence.
A man who is already genetically susceptible to male-pattern baldness and who starts a GLP-1 drug faces a compounded risk — his existing genetic vulnerability plus the additional 7% signal from GLP-1 receptor activity.
The study could only confirm this pattern in men, because male androgenetic alopecia has been far more extensively studied in large genetic databases. Women are not off the hook — hair thinning has been widely reported by female GLP-1 users — but the genetic evidence for a causal link in women does not yet exist. Dr. Petukhova has indicated she plans to investigate this.

It is also worth noting that the study population was predominantly White. Androgenetic alopecia prevalence and genetic architecture vary across ethnicities, so the 7% figure may not translate directly to men of other backgrounds.

What is androgenetic alopecia, and why does GLP-1 receptor activity matter to hair follicles?

Androgenetic alopecia is the most common form of hair loss in both men and women, characterized by a genetically programmed sensitivity of hair follicles to dihydrotestosterone (DHT), a derivative of testosterone. In men, it typically presents as a receding hairline and thinning at the crown; in women, diffuse thinning across the top of the scalp is more common.

The GLP-1 receptor (GLP1R) is a G-protein-coupled receptor expressed in multiple tissues throughout the body, including the pancreas, brain, heart, and — critically — in or near hair follicles. GLP-1 receptor agonist drugs bind to this receptor to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.

What is not yet fully understood is the precise mechanism by which GLP-1 receptor signaling interacts with hair follicle biology. Dr. Petukhova has said more research is needed to determine exactly how GLP-1 activity might interfere with hair follicle growth. The current study establishes that a genetic link exists — it does not yet explain the molecular pathway through which that link operates.

One hypothesis is that GLP-1 receptors expressed in or near the dermal papilla (the cluster of cells at the base of each hair follicle that controls hair growth) could, when overstimulated, disrupt the normal hair growth cycle. Another possibility involves the systemic hormonal and metabolic changes that GLP-1 drugs induce, which may create an environment less favorable to follicle maintenance in men who are already genetically primed for hair loss.

What do regulators and drug manufacturers say about GLP-1 hair loss?

The regulatory picture is still developing. The FDA has indicated it is evaluating hair loss as a potential safety signal for GLP-1 receptor agonists, particularly semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). The agency's Adverse Event Reporting System has logged hair loss reports for both drug classes, though spontaneous reporting systems capture only a fraction of actual adverse events.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) received 399 reports of hair loss related to tirzepatide in 2026 year-to-date, alongside 541 reports in 2025. For semaglutide, the MHRA received 148 reports in 2026 and 164 in 2025. These numbers reflect reported cases, not incidence rates, and should be interpreted cautiously — but the year-over-year consistency suggests this is not a disappearing signal.

An estimated 12% of Americans have used GLP-1 drugs solely for weight loss, including one-fifth of women aged 50 to 64. Since Ozempic was first approved by the FDA in 2020, prescriptions have more than tripled. With tens of millions of people now using these medications, even a modest per-user risk of hair loss translates into a large absolute number of affected individuals.

Neither Novo Nordisk (maker of Ozempic and Wegovy) nor Eli Lilly (maker of Zepbound and Mounjaro) has updated its prescribing information to include androgenetic alopecia as a labeled risk based on the new genetic study. Label changes typically require regulatory review and additional clinical data.

Could pre-screening or combination treatments prevent GLP-1-related hair loss?

This is where the research points toward a genuinely actionable future, even if the tools are not yet ready for clinical deployment.

"Our findings suggest that, if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications," said Dr. Petukhova. "We could also envision these findings leading to some GLP-1 users being prescribed combination treatments to prevent hair loss, such as minoxidil or some other drug."

Minoxidil is already a well-established, FDA-approved treatment for androgenetic alopecia in both men and women. It works by prolonging the anagen (growth) phase of the hair cycle and widening blood vessels around hair follicles. If a man starting a GLP-1 drug is identified as genetically high-risk for androgenetic alopecia, prophylactic minoxidil could theoretically blunt the additional hair loss risk. No clinical trial has tested this combination yet — but the biological rationale is sound.

Genetic screening for androgenetic alopecia risk is already commercially available through direct-to-consumer genomics companies, though the predictive accuracy of these tests varies. The NYU Langone findings add scientific weight to the idea that such screening could have clinical utility in the GLP-1 prescribing context.

For men already experiencing hair thinning on GLP-1 drugs, the existing evidence on telogen effluvium offers some reassurance: many GLP-1 users have found that hair growth resumes several months after their weight stabilizes. For men with underlying androgenetic alopecia, however, the genetic study suggests that some of the hair loss may not be purely telogen effluvium — meaning it may not fully reverse once weight stabilizes. This is an important distinction that clinicians and patients should discuss.

What should men currently taking GLP-1 drugs do?

The evidence does not support stopping GLP-1 medications because of hair loss concerns. These drugs carry substantial, well-documented benefits for glycemic control, cardiovascular risk reduction, and weight management — benefits that, for most patients, far outweigh a 7% incremental hair loss risk.

What the evidence does support is informed discussion. Men who are already experiencing male-pattern baldness or who have a strong family history of it should mention this to their prescribing physician before starting a GLP-1 drug. Dermatologists and endocrinologists may increasingly need to coordinate care for patients on these medications.

Practical steps that are reasonable while awaiting more definitive guidance:

Ensure adequate nutritional intake, particularly iron, zinc, and biotin, since caloric restriction on GLP-1 drugs can deplete micronutrients that support hair growth.
Monitor hair density in the months after starting a GLP-1 drug, particularly if there is a personal or family history of androgenetic alopecia.
Discuss the option of topical minoxidil with a dermatologist if significant shedding occurs, especially if it does not resolve after weight stabilizes.
Avoid abrupt discontinuation of GLP-1 drugs based on hair loss alone without medical advice, as weight regain and metabolic deterioration carry their own health risks.

If you are exploring hair-supportive products while managing GLP-1-related thinning, formulas designed for scalp health may help maintain the follicular environment. Our guide to best amino acid scalp shampoos for daily use covers options that support scalp integrity without harsh stripping, and our roundup of best Japanese hair growth serums for thinning hair reviews topical actives with clinical backing for follicle support.

What are the limitations of the current evidence?

Transparency about what this research does and does not prove matters here.

The NYU Langone study uses Mendelian randomization — a powerful design for inferring causality, but not a randomized controlled trial. The 7% risk estimate is derived from genetic proxies for GLP-1 receptor activity, not from directly observing hair loss in men taking GLP-1 drugs over time. A prospective clinical trial tracking hair loss in GLP-1 users stratified by GLP1R genotype would provide stronger evidence.

The study populations were predominantly White, limiting generalizability. The analysis was restricted to men because large-scale genetic data on female androgenetic alopecia is comparatively sparse — this is a gap in the field, not a finding that women are unaffected.

The BMJ observational study, while large (~50,000 patients), compared GLP-1 users to users of other diabetes drugs. People prescribed GLP-1s may differ systematically from those prescribed SGLT-2 or DPP-4 inhibitors in ways that influence hair loss risk, even after statistical adjustment. The MHRA and FDA adverse event data reflect spontaneous reporting, which is subject to underreporting and reporting bias.

Taken together, the evidence is converging but not yet definitive. The biological mechanism linking GLP-1 receptor activity to hair follicle disruption remains uncharacterized at the molecular level. Until that mechanism is understood, the 7% figure should be treated as a signal warranting clinical attention, not a certainty warranting alarm.

What comes next in the research?

Dr. Petukhova and her team at NYU Langone have indicated several planned next steps. First, they intend to investigate whether the same genetic connection found in men applies to women — a critical gap given that nearly half of White American females over age 50 are affected by androgenetic alopecia, particularly those who are postmenopausal, and that women make up a large share of GLP-1 users.

Second, the team plans to pursue mechanistic research to understand exactly how GLP-1 receptor activity interferes with hair follicle biology. Identifying the molecular pathway would open the door to targeted interventions — drugs that could be co-prescribed with GLP-1 agonists to protect hair follicles in high-risk individuals.

The BMJ research group from the University of Pennsylvania has also flagged the need for longer follow-up studies to determine whether hair loss in GLP-1 users is truly transient (as telogen effluvium typically is) or whether a subset of users experience persistent loss that does not recover after weight stabilization.

Regulatory agencies on both sides of the Atlantic are watching. If the FDA's ongoing safety evaluation of the GLP-1 hair loss signal results in a label update, that would represent a significant shift in how these drugs are prescribed and monitored — particularly for older men with a genetic predisposition to male-pattern baldness.

The September 2026 NYU Langone study is the most scientifically rigorous evidence yet that GLP-1 drugs and hair loss are connected by more than coincidence or caloric restriction. The question is no longer whether the link is real. The questions are how strong it is, who it affects most, and what can be done about it.